Scholarlink

<p>The purpose of this study was to design, synthesize, characterize, and evaluate the functionalized nanoliposomes containing levodopa and ibuprofen and conjugated with Anti-alpha-synuclein aptamer (FNLLICAASA). In this study, different aptamer sequences were designed and the best aptamer was selected. Then, the FNLLICAASA was synthesized, characterized, and the amount of dopamine level changes in SH-SY5Y cells after exposure to FNLLICAASA was evaluated. Also, the interferon-gamma (<i>INFG</i>) expression was assessed. The binding of FNLLICAASA to SH-SY5Y cells was also investigated using a fluorescent microscope and flow cytometry. The results of molecular docking and molecular dynamics simulation showed that aptamer APT46 with GAGGAG sequence was the best-chosen aptamer. The FNLLICAASA have a size range of 120 to 310&#xa0;nm with an average positive zeta potential of 30 mV. The dopamine level change was increased in treated SH-SY5Y nerve cells, indicating the dopaminergic property of FNLLICAASA. Also, the expression of <i>INFG</i> was decreased in treated SH-SY5Y nerve cells, indicating the anti-neuroinflammatory property of FNLLICAASA. The binding tests showed the targeted binding of synthesized nanoliposomes to alpha-synuclein molecules on the cell surface of SH-SY5Y cells.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Dopaminergic and Anti-Neuroinflammatory Properties of Functionalized Nanoliposomes Containing Levodopa and Ibuprofen and Conjugated with Anti-Alpha-Synuclein Aptamer

  • 期刊论文

  • 发表日期：

    2025年6月9日

查看全文
  • Sara Mostafa-Tehrani,
  • Mostafa Saffari,
  • Ebrahim Balali,
  • Ramona Khadivi,
  • Ali Jebali

摘要

The purpose of this study was to design, synthesize, characterize, and evaluate the functionalized nanoliposomes containing levodopa and ibuprofen and conjugated with Anti-alpha-synuclein aptamer (FNLLICAASA). In this study, different aptamer sequences were designed and the best aptamer was selected. Then, the FNLLICAASA was synthesized, characterized, and the amount of dopamine level changes in SH-SY5Y cells after exposure to FNLLICAASA was evaluated. Also, the interferon-gamma (INFG) expression was assessed. The binding of FNLLICAASA to SH-SY5Y cells was also investigated using a fluorescent microscope and flow cytometry. The results of molecular docking and molecular dynamics simulation showed that aptamer APT46 with GAGGAG sequence was the best-chosen aptamer. The FNLLICAASA have a size range of 120 to 310 nm with an average positive zeta potential of 30 mV. The dopamine level change was increased in treated SH-SY5Y nerve cells, indicating the dopaminergic property of FNLLICAASA. Also, the expression of INFG was decreased in treated SH-SY5Y nerve cells, indicating the anti-neuroinflammatory property of FNLLICAASA. The binding tests showed the targeted binding of synthesized nanoliposomes to alpha-synuclein molecules on the cell surface of SH-SY5Y cells.

Graphical Abstract